Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Atopic Dermatitis
Interventions
DRUG

Placebo

A total of 4 doses were administered.

DRUG

Dupilumab

A total of 4 doses were administered.

OTHER

Background treatment

Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.

Trial Locations (13)

10117

Berlin

10827

Berlin

Unknown

Kogarah

Woolloongabba

Carlton

Nedlands

Hanover

Bonn

Gera

Münster

Sydenham

Caversham

Auckland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY